Everything below concerns anti-doping. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
In 1886, Eugen Goldstein discovered canal rays (also known as anode rays) exiting from perforations in the discharge tube. Wilhelm Wien in 1898 showed that these rays had a charge opposite to the negative electrons discovered by J. J. Thomson, but with a much higher mass to charge ratio. Later that year Thomson was able to determine a value for the magnitude of the electric charge, e, and show that the canal rays included material with charge-to-mass ratio (q/m) consistent with the hydrogen ion. Following the discovery of the atomic nucleus by Ernest Rutherford in 1913, Antonius van den Broek proposed that the place of each element in the periodic table (its atomic number) is equal to its nuclear charge. Van den Broek speculated that the nucleus contained alpha particles with four positive charges and two electrons, the first version of the nuclear-electron hypothesis. (The modern model of two positive protons and two neutrons would take many years to discover). Also in 1913 Niels Bohr presented a theory of atomic structure which predicted electronic transitions related to nuclear charge. This was confirmed experimentally by Henry Moseley in 1913 when he showed that the energy of X-ray spectra lines of many elements followed a pattern based on atomic number. In 1919, after a long series of sporadic experiments interrupted by WWI, Rutherford discovered what he called artificial disintegration of nitrogen atoms.
1979 Elected member, European Molecular Biology Organization. 1987 Meyenburg Prize for Cancer Research. 1995 Elected member, Academia Europaea. 1997 Doctorate honoris causa, Pomeranian Medical Academy, Szczecin, Poland. 1998 Carl Zeiss Prize, German Society of Cell Biology, (shared with Klaus Weber). 1998 Helena Rubenstein / UNESCO Prize for Women in Science (UK). 2002 L'Oréal / UNESCO Prize for Women in Science. 2003-2006 President of the International Union of Biochemistry and Molecular Biology (IUBMB). 2005 Outstanding Science Alumni Award, Pennsylvania State University, USA. 2014. Federal Cross of Merit, 1st Class, Federal Republic of Germany. 2007 Dorothea Schlözer Medal, University of Göttingen, Germany.
=== Other uses === PVDF is used for specialty monofilament fishing lines, sold as fluorocarbon replacements for nylon monofilament. The surface is harder, so it is more resistant to abrasion and sharp fish teeth. Its refractive index is lower than nylon, which makes the line less discernible to fish eyes. It is also denser than nylon, making it sink faster towards fish. PVDF is used for specialty roofing coatings to improve UV resistance and increase roof color retention.
Lately Executive Director, City Building. For services to Equality and Inclusion in Construction. Dr. Shriti Pattani. Lately President, The Society of Occupational Medicine. For services to Occupational Health. Nicola Heather Anne Patterson. Lately Director of Nursing, South Eastern Health and Social Care Trust. For services to Health and Social Care in Northern Ireland. Professor Rupert Mark Pearse. Professor of Intensive Care Medicine, Queen Mary University of London. For services to Intensive Care Medicine. Amy Sarah Perrin. Founder, The Marmalade Trust. For services to Older People. Oscar Victor Pinto-Hervia. Founder, Hervia. For services to Fashion and to Charity. Dr. Madsen Pirie. President, Adam Smith Institute. For services to Public Policy. Mary Margaret Portas. Retail Consultant and Broadcaster. For services to Business, to Broadcasting and to Charity. Alexander Reedijk. General Director, Scottish Opera. For services to the Performing Arts in Scotland. Marvin Rees. Mayor, Bristol City Council. For services to Local Government. Professor Julian Daryl Richards. Professor of Archaeology, University of York. For services to Heritage and Digital Archiving. Julian Richmond-Watson. Chair, Thoroughbred Breeders Association. For services to the British Horseracing Industry. José Salvador Riera. Deputy Director, Communications, Department for Culture, Media and Sport. For Public Service. Martin John Rigley, MBE. Lately Managing Director, Lindhurst Engineering Ltd. For services to the East Midlands Covid-19 Response and to the community in Derbyshire and Nottinghamshire.
Sources: en.wikipedia.org
No trade, no cultural exchanges, no political exchanges, no cooperation on anything that resembles common interests." In August 2020, a La Trobe University professor Nick Bisley wrote that the US–China rivalry "will be no Cold War" but rather will "be more complex, harder to manage, and last much longer". He further wrote that comparing the old Cold War to the ongoing rivalry "is a risky endeavour". In September 2020, the UN secretary-general António Guterres warned that the increasing tensions between the US under Trump and China under Xi were leading to "a Great Fracture" which would become costly to the world. CCP general secretary Xi Jinping replied by saying that "China has no intention to fight either a Cold War or a hot one with any country".
==== Season 3 ==== In the wake of Kendall's announcement, Logan temporarily steps back as CEO (appointing Gerri as his interim placement), negotiates a settlement with Marcia to ensure her cooperation, and names Shiv Waystar's President of Domestic Operations. Logan experiences a resurgence in health complications upon returning to New York, forcing his children to make a settlement with Sandy and Stewy without his input during the company's annual shareholder meeting. After Waystar and the Department of Justice also reach a settlement, Logan attempts to acquire streaming giant GoJo, but the company's CEO Lukas Matsson instead proposes the opposite, assuring Logan he will continue to control key assets. Logan decides to take up Matsson's offer without consulting his children, whose chances of leading the company are jeopardized with Matsson in control. Kendall, Shiv and Roman attempt to veto their father's decision via their stake in the family holding company. However, Logan and Caroline renegotiate their divorce settlement in time to deprive the children of their voting power, effectively leaving them powerless within the company. Tom is revealed to have tipped off Logan on his children's revolt.
=== Mimicry === Much like the Salticidae family of spiders, P. phalangioides also use mimicry as a predatory tactic to subdue their prey; however, unlike jumping spiders, P. phalangioides do not rely on vision for predation. This mimicry consists of creating specialized vibrations to trick the prey into thinking that it has caught an insect or another spider. The prey then slowly approaches its supposed catch at which point the P. phalangioides spider raises up on its long legs. The spider patiently waits until the exact moment at which the prey touches one of its legs. Then, the P. phalangioides spider quickly immobilizes its prey by using its legs to wrap it up in layers of silk. Its long legs give it plenty of distance from the prey to avoid being bitten in retaliation. After immobilizing its prey, P. phalangioides can administer their venomous bite to the prey and consume it. Even forms of prey that do not fully make it onto the web of P. phalangioides are not safe. Often, prey will trip over the edges of the web, thus providing P. phalangioides with an optimal time to attack. P. phalangioides is capable of clinging onto their web with two of their legs while the rest of their body leans out of the web and shoots silk in the direction of the prey to subdue it.
Corn (maize) became a staple food in the southeast United States and in parts of Europe. A disease that was characterized by dermatitis of sunlight-exposed skin was described in Spain in 1735 by Gaspar Casal. He attributed the cause to poor diet. In northern Italy it was named "pellagra" from the Lombard language (agra = holly-like or serum-like; pell = skin). In time, the disease was more closely linked specifically to corn. In the US, Joseph Goldberger was assigned to study pellagra by the Surgeon General of the United States. His studies confirmed a corn-based diet as the culprit, but he did not identify the root cause. Nicotinic acid was extracted from liver by biochemist Conrad Elvehjem in 1937. He later identified the active ingredient, referring to it as "pellagra-preventing factor" and the "anti-blacktongue factor." It was also referred to as "vitamin PP", "vitamin P-P" and "PP-factor", all derived from the term "pellagra-preventive factor". In the late 1930s, studies by Tom Douglas Spies, Marion Blankenhorn, and Clark Cooper confirmed that nicotinic acid cured pellagra in humans. The prevalence of the disease was greatly reduced as a result. Nicotinic acid was initially synthesized by oxidizing nicotine with potassium chromate and sulfuric acid. Hence, in 1942, when flour enrichment with nicotinic acid began, a headline in the popular press said "Tobacco in Your Bread." In response, the Council on Foods and Nutrition of the American Medical Association approved of the Food and Nutrition Board's new names niacin and niacin amide for use primarily by non-scientists.
=== Solid culture media === Agarose plate may sometimes be used instead of agar for culturing organisms as agar may contain impurities that can affect the growth of the organism or some downstream procedures such as polymerase chain reaction (PCR). Agarose is also harder than agar and may therefore be preferable where greater gel strength is necessary, and its lower gelling temperature may prevent causing thermal shock to the organism when the cells are suspended in liquid before gelling. It may be used for the culture of strict autotrophic bacteria, plant protoplast, Caenorhabditis elegans, other organisms and various cell lines.
Sources: en.wikipedia.org
Benzalkonium chloride – "quat" disinfectant that attacks membranes Bethoxazin – "new broad spectrum industrial microbicide" in 2012, noted as "Canceled in U.S." in 2022 PubChem-EPA query Cybutryne – banned since 2023 in ship paint Dichlone – quinone fungicide/algaecide, not persistent in soil Dichlorophen – also kills invertebrate animals and bacteria Diuron – herbicide/algaecide, inhibits photosynthesis Endothal – herbicide/algaecide, inhibits protein phosphatase 2A Fentin – quinone fungicide/algaecide, discontinued Isoproturon – selective substituted urea herbicide, discontinued Methabenzthiazuron – substituted urea herbicide, discontinued Nabam – fungicide/algicide discontinued in the EU over cancer Oxyfluorfen – herbicide, "very toxic to aquatic life with long lasting effects" Pentachlorophenyl laurate Quinoclamine – herbicide/algicide, not used in most of the EU Quinonamid Simazine – herbicide/algaecide, inhibits photosynthesis Terbutryn Tiodonium
Severe combined immunodeficiencies (SCIDs) are a rare group of genetic disorders characterized by the body's inability to create functional T cells and B cells. SCIDs are the most severe form of primary immunodeficiency, making their sufferers extremely vulnerable to infection due to their highly compromised immune system. There are at least seven different known genes in which mutations lead to a form of SCID, each of which has different clinical presentations. SCID involves defective antibody response due to either direct involvement with B lymphocytes or through improper B lymphocyte activation due to non-functional T-helper cells. Consequently, both "arms" (B cells and T cells) of the adaptive immune system are impaired due to a defect in one of several possible genes. Some SCID sufferers, such as David Vetter, have become famous for living in a sterile environment to avoid infection, leading to the name bubble boy disease and bubble baby disease. SCID patients are usually affected by severe bacterial, viral, or fungal infections early in life and often present with interstitial lung disease, chronic diarrhea, and failure to thrive. Ear infections, recurrent Pneumocystis jirovecii pneumonia, and profuse oral candidiasis commonly occur. These babies, if untreated, usually die within one year due to severe, recurrent infections unless they have undergone successful hematopoietic stem cell transplantation or gene therapy in clinical trials.
=== Acute kidney injury === Ferroptosis occurs during acute kidney injury in various cellular and animal models. Deficiencies in ferroptosis suppressor enzymes such as GPX4 and FSP1 sensitize kidneys to tubular ferroptosis during kidney IRI, thus inhibition of ferroptosis may be of therapeutic benefit. However, in premenopausal women this therapeutic potential might be limited due to intrinsic anti-ferroptotic effects of estrogen. During chemotherapy treatment, ferroptosis contributes to acute kidney injury. Reagents to image ferroptosis have been developed to monitor anticancer drug-induced acute kidney injury in mouse models.
Alkylating agents are the oldest group of chemotherapeutics in use today. Originally derived from mustard gas used in World War I, there are now many types of alkylating agents in use. They are so named because of their ability to alkylate many molecules, including proteins, RNA and DNA. This ability to bind covalently to DNA via their alkyl group is the primary cause for their anti-cancer effects. DNA is made of two strands and the molecules may either bind twice to one strand of DNA (intrastrand crosslink) or may bind once to both strands (interstrand crosslink). If the cell tries to replicate crosslinked DNA during cell division, or tries to repair it, the DNA strands can break. This leads to a form of programmed cell death called apoptosis. Alkylating agents will work at any point in the cell cycle and thus are known as cell cycle-independent drugs. For this reason, the effect on the cell is dose dependent; the fraction of cells that die is directly proportional to the dose of drug. The subtypes of alkylating agents are the nitrogen mustards, nitrosoureas, tetrazines, aziridines, cisplatins and derivatives, and non-classical alkylating agents. Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan. Nitrosoureas include N-Nitroso-N-methylurea (NMU), carmustine (BCNU), lomustine (CCNU) and semustine (MeCCNU), fotemustine and streptozotocin (STZ). Tetrazines include dacarbazine, mitozolomide and temozolomide. Aziridines include thiotepa, mitomycin and diaziquone (AZQ).
=== Mass spectrometer === Quadrupole, magnetic sector, and time-of-flight (TOF) are the three mass spectrometers (MS) used in SIMS. For SSIMS, the primary requirement is low primary-ion flux density, which results in extremely low secondary ion yield (10−3 – 10−8 atoms/cm3). Hence, there is a need to collect almost all the secondary ions. High transmission (0.5–1) of TOF maximizes the sensitivity (104 times that of quadrupole MS). Parallel detection together with reasonable mass resolution and high mass range (m/z > 103) are among its other major advantages. Ions are accelerated to a given potential so that they have the same kinetic energy, resulting in ions of different mass:charge (m/e) ratio having different velocities. These ions then pass through a region of field-free space in the flight tube, and spread out in time, with the higher-mass ions arriving later at the end of the flight tube, where a time-sensitive detection system produces a mass spectrum. The primary ions are pulsed into short bursts of less than 10 ns (the time scale of secondary-ion emission after impact is negligible (<10−12 s)). The primary beam is pulsed by a rapid deflection across a small aperture or by off-axis deflection, followed by a curved magnetic field to compress the pulse in space. There are very high accelerating fields at the sample (high extraction voltage and small (mm) extraction gaps) to reduce the initial energy spread of the secondary ions. Some TOF systems further compensate for this energy spread by using nonlinear flight tubes.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.